Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Soliqua 100/33 (insulin glargine/lixisenatide) and Ozempic (semaglutide) are both injectable medications used to treat Type 2 diabetes. They both contain glucagon-like peptide-1 (GLP-1) agonists, which help lower blood sugar levels. However, Soliqua 100/33 is a combination medication that also contains insulin glargine, a long-acting insulin. Soliqua 100/33 is injected once daily, whereas Ozempic is injected once weekly. Soliqua 100/33 must be taken within an hour before your first meal, while Ozempic can be taken at any time of the day, with or without food. Both medications can cause nausea and diarrhea and may increase your risk for some types of thyroid cancer.
Soliqua 100/33
Ozempic (semaglutide)
Soliqua 100/33
Ozempic (semaglutide)
Summary of Soliqua 100/33 vs. Ozempic
Summary for Insulin / GLP-1 agonist
Prescription only
Soliqua 100/33 is a combination medication for diabetes that contains insulin glargine (a long-acting insulin) and lixisenatide (a glucagon-like peptide-1 (GLP-1) receptor agonist). It helps manage blood sugar levels along with diet and exercise in adults with Type 2 diabetes. The medication comes as a prefilled pen and is injected under the skin once a day within 1 hour before you eat your first meal of the day. Soliqua 100/33 commonly causes stomach-related side effects like nausea and diarrhea.
Summary for GLP-1 agonist
Prescription only
Ozempic (semaglutide) is a prescription injection used with diet and exercise to help manage Type 2 diabetes in adults. It's also FDA approved to lower the risk of heart attack, stroke, and heart-related death in those with Type 2 diabetes and heart disease. In addition, it can reduce the risk of worsening kidney problems in people with Type 2 diabetes and chronic kidney disease (CKD). Ozempic (semaglutide) is a GLP-1 agonist that's injected under the skin once a week. Common side effects include nausea, vomiting, and diarrhea.